NCT03288870 - Efficacy, Safety and Pharmacokinetics of BCD-100 (Anti-PD-1) Monotherapy as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (DOMINUS) | Biotech Hunter

Enrollment

218

Participants

Timeline

Start Date

September 19, 2017

Primary Completion Date

August 10, 2020

Study Completion Date

August 10, 2021

Conditions

Non Small Cell Lung Cancer Stage IIIBNon-Small Cell Carcinoma of Lung, TNM Stage 4

Interventions

DRUG

BCD-100

monoclonal antibody to PD-1 receptor

DRUG

Docetaxel

Chemotherapy drug (taxane)

Trial Locations (8)

N.N. Burdenko General Military Clinical Hospital, Moscow

Arkhangelsk District Clinical Oncology Dispensary, Arkhangelsk

Saint Petersburg City Clinical Oncology Center, Saint Petersburg

N.N.Petrov Oncology Research Center, Saint Petersburg

Clinical Oncology Dispensary N1, Krasnodar

Pyatigorsk Oncology Center, Pyatigorsk

Republican Clinical Oncology Dispensary of Ministry of Health republic Bashkortostan, Ufa

Gomel Regional Clinical Oncology Dispensary, Homyel